Pfizer Research Grant Request for Proposals Competitive Grant Program – Pfizer Internal Review Process AI-Enabled Models for Timely COVID-19 Treatment with Nirmatrelvir/Ritonavir: Eligibility & Drug-Drug Interaction Management
Pfizer funds AI-driven research to optimize safe, timely outpatient COVID-19 treatment with nirmatrelvir/ritonavir, focusing on eligibility assessment and drug-drug interaction management.
Funder: Pfizer Inc.
Due Dates: July 7, 2026 (Submission deadline)
Funding Amounts: Up to $500,000 USD per project (max 2 years); total program budget $1,000,000 USD.
Summary: Supports AI-driven research to improve timely, safe outpatient COVID-19 treatment with nirmatrelvir/ritonavir, focusing on eligibility assessment and drug-drug interaction management.
Key Information: Only institutions in Australia, Canada, Germany, Greece, Japan, Korea, or Taiwan are eligible.
Description
This competitive grant program from Pfizer seeks research proposals aimed at enhancing safe and timely access to outpatient antiviral COVID-19 treatment with nirmatrelvir/ritonavir. The focus is on leveraging artificial intelligence (AI) and advanced clinical decision support to:
- Identify patient eligibility for antiviral treatment based on up-to-date guidelines and real-world clinical data.
- Proactively manage clinically significant drug-drug interactions (DDIs) to optimize disease management and patient safety.
Projects should address barriers to delivering outpatient COVID-19 therapy, ensuring treatment within the recommended time window, and develop tools that guide medication adjustments and monitoring for improved clinical outcomes.
